- Accredited testing of cannabis products is becoming a crucial health care initiative
- Cannabis testing regulations vary state-by-state where cannabis is legal
- EVIO testing labs provide quality control testing, advisory services to regulated cannabis industry
- Testing services offered nationwide, with eight labs in five states and expansion opportunities in another four states and Canada
EVIO, Inc. (OTCQB: EVIO), a health sciences company focused on analyzing cannabis, continues to move the bar higher and set the standard when it comes to testing cannabis in each of its laboratory settings in states where the highly regulated plant is now legal. Headquartered in Oregon, EVIO Labs specializes in testing cannabis and industrial hemp flower, extracts and infused products. Its laboratories offer a crucial selection of analytical tests that meet international standards and state-regulated testing guidelines. EVIO Labs recently expanded its testing capabilities with the addition of delta-8 THC to its analyte list for cannabinoid profiling.
Recent recalls of certain cannabis products (http://cnw.fm/Fl4dC), prompted by the discovery of mold and other identifiable contaminants in the recalled items, show the dire need for quality laboratory testing services. While links between illness and tainted cannabis are not well documented, anecdotal accounts include worrisome stories about cannabis infected with mites, mold or yeast, or grown with potentially cancer-causing pesticides (http://cnw.fm/ZSvh6).
EVIO’s dedication to attaining the highest of accreditation standards is a key element of the company’s success and one that should matter most to cannabis consumers, who are often seeking relief from specific ailments. In fact, EVIO Labs Florida recently achieved ISO 17025 accreditation, becoming the first accredited cannabis testing lab in the state (http://cnw.fm/zII4S). This achievement, which marks the highest recognized quality standard in the world for calibration and testing laboratories, means that EVIO Labs Florida consistently produces precise and accurate tests that are implemented under a rigorous quality management system (http://cnw.fm/vWg6t).
Notably, EVIO Labs Colorado has also completed its ISO accreditation, representing an important step in expanding the company’s footprint in the lucrative Colorado cannabis market. The company’s laboratories in Southborough, Massachusetts, and Berkeley, California, are expected to attain ISO accreditation by the end of Q2 2018.
For consumers and state regulators alike, knowing that a laboratory meets the stringent certification requirements established by the International Organization for Standardization (“ISO”) offers an important distinction as more states begin to legalize cannabis and must set their own health and safety standards (http://cnw.fm/VxSx6). EVIO Labs is on track to open 18 cannabis testing laboratories by the end of 2018 at locations dotted around the United States. The company is evaluating lab opportunities in Canada as well, in addition to finalizing discussions for several regional service centers.
EVIO continues to build its core management team with the addition of Al Lustig as president and Ron Russak as vice president of operations. Lustig comes to EVIO from pharmaceutical giant Pfizer, where he built, led and helped manage many district, regional and national sales organizations. Lustig’s role at EVIO includes driving growth in new and existing markets, including international sales and operational strategies. Russak, who spent 17 years at Quest Diagnostics, will spearhead the growth and profitability of EVIO’s expanding portfolio of cannabis testing labs.
A recently released letter to shareholders (http://cnw.fm/7mdLk) offers additional information on these important developments.
For more information, visit the company’s website at www.EVIOLabs.com
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com